The Government has insisted US drugs giant Merck’s move to ditch plans for a £1 billion London centre was a “commercial decision” as it came under fire for under-investment in the sector.
Merck, known as MSD in the UK and Europe, dealt a major blow to the UK’s life sciences sector on Wednesday evening when it announced it was scrapping a planned research centre in London’s King’s Cross, which was already under construction and due to open in 2027.
